The FDA has released a statement announcing the end of the nationwide shortage of sodium chloride 0.9% injection products.

The FDA touts this announcement as a sign of the “close collaboration between the FDA, the Administration for Strategic Preparedness and Response, and [their] industry partners.” While the shortage was ongoing, the FDA had used “regulatory tools to help increase supplies available to hospitals to meet patient needs.” They “conducted scientific and regulatory assessments to help facilitate the temporary importation of intravenous solutions and expedited reviews to increase manufacturing capacities and extend product expiry.”

These products will now be removed from the FDA list of current shortages, and the agency now recommends hospitals, health systems, and clinics use the drug when available. Other IV fluids remain in shortage.

An AHA release about the end of this shortage says that the supply was “significantly impacted last year when Hurricane Helene disrupted production at a Baxter manufacturing facility in North Carolina. The company produces 60% of the country’s supply of IV solutions.”